Shares of BioCryst Pharmaceuticals Inc. (BCRX) are down over 40% from their 52-week high of $11.31, recorded last June, and trade around $6.
This commercial-stage biotechnology company markets ORLADEYO, a plasma kallikrein inhibitor approved for the prophylaxis of hereditary angioedema (HAE) in patients aged 2 years and older, and a non-core product, RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.